As one of the most promising players in immuno-oncology, Genenta, the Italo-American biotech company, outlines its roadmap before investors and international stakeholders in Qatar.

A new amendment of the previous agreement introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta’s cell therapy product

WHO relaunches global health with the 2025–2028 strategy, focusing on equity, resilience, and collaboration. Climate, access to medicines, innovation, and stronger health systems are at the heart of an agenda that also calls the pharmaceutical industry to action.